Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Specific Risk

The legacy of general health and science information has long provided a foundational framework for understanding broad physiological principles and the interplay between environmental factors and bodily systems. Within this context, public health discourse has historically emphasized the importance of maintaining skeletal integrity and oral hygiene as cornerstones of overall well-being. This heritage includes the dissemination of knowledge regarding the effects of various substances on bone metabolism and dental health, often drawing from observational studies and clinical reports that highlight potential risks associated with pharmaceutical interventions. As this informational landscape evolves, a natural pivot emerges toward more specialized domains of inquiry, particularly those involving occupational or therapeutic exposures.

Bridging to Bisphosphonate Therapy

The transition from general health awareness to a focused examination of specific agents requires careful consideration of how routine medical treatments may intersect with rare but serious adverse outcomes. In this regard, the discussion of bisphosphonate therapy—commonly prescribed for osteoporosis and other bone conditions—offers a pertinent bridge. The shift in focus moves from broad health maintenance to the nuanced assessment of exposure scenarios, where the cumulative effects of a drug like Fosamax on jawbone integrity become a matter of clinical and occupational concern. This pivot underscores the need to evaluate risk within the context of prolonged use, without delving into mechanistic pathways, thereby maintaining a neutral academic stance while advancing the inquiry into causation.

Clinical Evidence and FDA Labeling

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The question of whether Fosamax causes ONJ is addressed through clinical reports, mechanistic understanding, and risk factor analysis. Clinical evidence from the FDA-approved labeling indicates that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling explicitly states that osteonecrosis of the jaw has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This establishes a documented association between Fosamax use and ONJ, though the labeling notes that in placebo-controlled clinical studies of Fosamax, the percentages of patients with jaw-related symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse event, its incidence in controlled trials was not statistically elevated, likely due to the rarity of the condition and the specific risk factors involved.

Mechanistic Pathways and Risk Factors

Mechanistic pathways linking Fosamax to ONJ are supported by research on jawbone-specific responses. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Bisphosphonates like Fosamax inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover. In the jaw, which undergoes frequent remodeling due to dental procedures and infection, this suppression may impair healing and lead to necrotic bone exposure. The labeling identifies known risk factors for ONJ, including invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Temporal Relationship and Causation

Regarding the timeline between exposure and documented harm, the labeling reports that the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This wide range indicates that ONJ can develop shortly after initiation or after prolonged use. Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This rechallenge phenomenon supports a causal relationship, as symptoms reappear upon re-exposure. Adequacy of warnings regarding Fosamax and ONJ is addressed in the labeling. The warnings section includes a dedicated subsection (5.4 Osteonecrosis of the Jaw) that describes the condition, associated risk factors, and management recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This provides actionable guidance for clinicians and patients. However, the labeling also notes that the optimal duration of Fosamax use has not been determined, and for patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This reflects ongoing uncertainty about long-term risk.

Considerations for Affected Patients

Causation-related considerations for affected patients involve evaluating individual risk factors. The labeling emphasizes that ONJ is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients with multiple risk factors, such as cancer, chemotherapy, or poor oral hygiene, are at higher risk. The temporal relationship between Fosamax initiation and ONJ onset, along with symptom improvement upon discontinuation and recurrence upon rechallenge, supports a causal link in susceptible individuals. However, the low incidence in controlled trials suggests that ONJ is not a common adverse effect and may require a predisposing context. In summary, Fosamax is associated with osteonecrosis of the jaw, as documented in FDA-approved labeling and supported by mechanistic research. The risk is influenced by duration of use, dental procedures, and other comorbidities. Warnings are provided in the labeling, and management strategies include discontinuation before invasive dental procedures. Affected patients should consider their individual risk profile and discuss with their healthcare provider.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the association between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that has been associated with osteonecrosis of the jaw (ONJ) in FDA-approved labeling. Clinical reports indicate ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in placebo-controlled trials, the incidence of jaw-related symptoms was similar between Fosamax and placebo groups, suggesting ONJ is rare and often requires additional risk factors.

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

How soon after starting Fosamax can ONJ develop?

The time to onset of ONJ symptoms can vary from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief after stopping the drug, but recurrence upon rechallenge supports a causal link.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.